Abstract:In 1992, in an effort to bring novel drugs to market more quickly and meet patient needs in a timely manner, the US Food and Drug Administration (FDA) pioneered an accelerated approval initiative on the basis of surrogate endpoints that are reasonably predictive of clinical benefit for the treatment of serious or life-threatening diseases. 1 US Food and Drug AdministrationAccelerated approval program. https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-programDate accessed: October 24, 2023 Google Scholar By contrast to regular approval, accelerated approval requires post-market confirmatory clinical trials to establish the clinical benefit of the drug, then a decision is made as to whether the approval should be converted to a traditional approval or whether the drug should be withdrawn from the market. 2 US Food and Drug AdministrationExpedited programs for serious conditions––drugs and biologics. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologicsDate accessed: October 24, 2023 Google Scholar In the past 3 years, this expedited pathway has attracted extensive criticism, including failure to complete confirmatory clinical trials in a timely manner, 3 Fashoyin-Aje LA Mehta GU Beaver JA Pazdur R The on- and off-ramps of oncology accelerated approval. N Engl J Med. 2022; 387: 1439-1442 Crossref PubMed Scopus (33) Google Scholar , 4 Gyawali B Kesselheim AS Ross JS The accelerated approval program for cancer drugs—finding the right balance. N Engl J Med. 2023; 389: 968-971 Crossref PubMed Scopus (9) Google Scholar use of surrogate endpoints (eg, progression-free survival) in confirmatory clinical trials, 5 Parikh RB Hubbard RA Wang E et al. Exposure to US cancer drugs with lack of confirmed benefit after US Food and Drug Administration accelerated approval. JAMA Oncol. 2023; 9: 567-569 Crossref PubMed Scopus (6) Google Scholar and failure to withdraw drugs quickly from the markets when they have been shown to not have clinical benefit. 6 Akhade A Sirohi B Gyawali B Global consequences of the US FDA's accelerated approval of cancer drugs. Lancet Oncol. 2022; 23: 201-203 Summary Full Text Full Text PDF PubMed Scopus (10) Google Scholar Concerns have also been raised that cancer drugs given accelerated approval by the FDA could lead to difficult decisions in other countries, especially in some low-income and middle-income countries that do not have their own regulatory agencies or that have weak regulatory capacity. 6 Akhade A Sirohi B Gyawali B Global consequences of the US FDA's accelerated approval of cancer drugs. Lancet Oncol. 2022; 23: 201-203 Summary Full Text Full Text PDF PubMed Scopus (10) Google Scholar , 7 Cramer A Sørup FKH Christensen HR Petersen TS Karstoft K Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?. Lancet Oncol. 2023; 24: e385-e394 Summary Full Text Full Text PDF PubMed Scopus (3) Google Scholar

Emergency Use Authorization of Medical Products

Current Regulatory Status in China of Drugs Withdrawn from the US FDA Accelerated Pathway: Implications for Regulation Globally

Comparison of regulatory approval system for medicines in emergency among Japan, the United States, the United Kingdom, Europe, and China

Analysis on Emergency Authorization Policies of Medical Products

U.S. Food and Drug Administration: Review for the Emergency Physician of Approval Process and Limitations

Public and health care provider attitudes, understanding, and behaviors regarding emergency use authorizations: a scoping literature review

Health Equity and Access to COVID-19 Treatments Available through Emergency Use Authorizations

Japan’s Special Approval for Emergency System During the COVID‐19 Pandemic

[Europe and medicines: role of the EMEA]

Analysis of emergency Drug Approval System in China and the United States under Public Health emergencies and its enlightenment to China

Comparative Analysis of Post-Authorization Measures for Advanced Medicinal Products Authorized in the European Union and in the United States of America Between 2009 and 2023

Comparative analysis of GMO regulatory requirements for AAV vectors in the EU and Japan focusing on the shedding data and containment measures

Regulatory approval pathways for anticancer drugs in Japan, the EU and the US

Roles and contributions of pharmacists in regulatory affairs at the Centers for Disease Control and Prevention for public health emergency preparedness and response

Clinical experience with intravenous zanamivir under an Emergency IND program in the United States (2011-2014)

Exploring status of emergency drugs and vaccine development in Covid-19 pandemic: an update

Comparison of approval procedures for medical devices in Europe and the USA

How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?

Evolution of FDA's NDA/BLA review process under PDUFA

The Role of the European Medicines Agency in the Safety Monitoring of COVID-19 Vaccines and Future Directions in Enhancing Vaccine Safety Globally

A Review of Regulatory Mechanisms Used by the WHO, EU, and US to Facilitate Access to Quality Medicinal Products in Developing Countries With Constrained Regulatory Capacities